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ABSTRACT 
INTRODUCTION: A 3 year analysis of the outcome of various types of management 
for Unexplained Infertility in Hospital USM (2010-2013) 
OBJECTIVE: To evaluate the outcome of patients diagnosed with Unexplained Infertility 
undergoing Expectant Management (EM) compared to Controlled Ovulation 
Hyperstimulation (COH) and Controlled Ovulation Hyperstimulation and Intrauterine 
Insemination (COH+IUI). The primary outcome is the pregnancy rate. The secondary 
outcomes are the ovarian response and the endometrial response among patients receiving 
stimulated cycles. Apart from that we have also assessed the risk of developing Ovarian 
Hyper-stimulation Syndrome (OHSS) and multiple pregnancy among these patients. 
STUDY DESIGN:  This is a retrospective and prospective cohort study among women with 
unexplained infertility from 1st December  2010 until 30st November 2013, aged 18-44 years 
old undergoing their treatment at Hospital Universiti Sains Malaysia (HUSM). The subjects 
were recruited from the infertility clinic at HUSM. They were given EM, COH or COH+IUI. 
RESULTS: Total of 109 patients was enrolled in this study; 36 patients under EM, 36 
patients under COH and 37 patients under COH+IUI. There were no significant statistical 
differences between the 3 treatment groups, in terms of the socio demographic and 
characteristics of unexplained infertility i.e. age, BMI, ethnicity, husband’s smoking status, 
type of infertility and duration of Infertility. (p-value > 0.05) 
There is a significant difference in terms of pregnancy rate between the 3 treatment groups 
(p-value = 0.00). In EM group, 17 patients (47.22%) managed to conceive within the 12 
months of follow-up. In the COH group, 13 of them (36.1%) managed to conceive using this 
regime .In COH+IUI group 2 of them (5.4%) managed to conceive using this regime, 1 
patient from using CC + IUI and another one from using recombinant FSH +IUI.  
XIV 
 
For correlation between ovarian response and pregnancy rate, result showed that patients in 
COH group had higher pregnancy rate with even 1 dominant follicle (69.2%) While in the 
COH+IUI group, the pregnancy rate is similar in patients with 1 dominant follicle and 2 
dominant follicles. As a whole, there is significant correlation between pregnancy rate and 
number of dominant follicles (p-value= 0.01) 
For correlation between endometrial receptivity and pregnancy rate, result showed that 
patients in COH group had higher pregnancy rate when the endometrial thickness is 
between 6-10mm (69.2%). In the COH+IUI group, there is no significant difference seen in 
terms of pregnancy rate in couples with ET 1-5mm and ET 6-10mm. As a whole, ET is not a 
significant predictor for pregnancy rate for stimulated cycles (p-value=0.55) 
There were no differences between COH and COH+IUI group in terms of risk of developing 
OHSS and rate of multiple pregnancies.  
CONCLUSION: Expectant management is comparable to COH and IUI in the management 
of unexplained infertility in terms of pregnancy rate. 
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ABSTRAK 
PENGENALAN: Analysis tentang keberkesanan pelbagai jenis perawatan untuk 
masalah ketidaksuburan tanpa sebab di Hospital USM untuk tempoh 3 tahun (201-
2013) 
OBJEKTIF: Untuk mengkaji keberkesanan perawatan tunggu dan lihat (Expectant 
Management (EM)) terhadap pesakit yang menghadapi masalah ketidaksuburan tanpa 
sebab, berbanding dengan pesakit yang menggunakan rawatan hiperstimulasi ovary 
terkawal (Controlled Ovulation Hyperstimulation (COH)) dan hiperstimulasi ovary terkawal 
dan permanian berhadas (Controlled Ovulation Hyperstimulation and Intrauterine 
Insemination (COH+IUI)). Kesan utama yang dikaji adalah kadar kehamilan. Kesan 
sampingan yang dikaji adalah kesan terhadap ovari dan kesan terhadap lapisan 
endometrium bagi pesakit yang mendapat perawatan hiperstimulasi ovary terkawal (COH) 
dan hiperstimulasi ovary terkawal dan permanian berhadas (COH+IUI). Selain daripada itu 
kami juga mengkaji kadar kesan sampingan seperti sindrom hiperstimulasi ovari (Ovarian 
Hyperstimulation Syndrome (OHSS)) dan kandungan kembar (Multiple Pregnancies). 
KAEDAH KAJIAN:  Ini adalah merupakan kajian retrospektif dan prospektif terhadap 
pesakit yang mengalami masalah ketidaksuburan tanpa sebab dari 1hb Disember 2010 
sehingga 31hb November 2013, berusia 18-40 tahun, yang mendapat perawatan di Klinik 
Infertilti, HUSM. Mereka telah dibahagikan di dalam 3 kumpulan berdasarkan rawatan yang 
diterima, perawatan tunggu dan lihat (EM), hiperstimulasi ovary terkawal (COH) dan 
hiperstimulasi ovary terkawal dan permanian berhadas (COH+IUI). 
KEPUTUSAN: Seramai 109 orang pesakit telah menyertai kajian ini, 36 pesakit dalam 
kumpulan perawatan tunggu dan lihat (EM), 36 pesakit dalam kumpulan hiperstimulasi ovary 
terkawal (COH) dan 37 pesakit dalam kumpulan hiperstimulasi ovari terkawal dan 
permanian berhadas (COH+ IUI). Kajian tidak mendapati sebarang perbezaan ketara dalam 
XVI 
 
kadar kehamilan berdasarkan faktor sosio demografik dan ciri-ciri ketidaksuburan tanpa 
sebab seperti umur pesakit wanita, “body mass index [BMI]”, kumpulan etnik, status 
merokok dikalangan suami, jenis infertiliti dan tempoh ketidaksuburan. 
Kajian menunjukkan perbezaan ketara dalam kadar kehamilan jika dibandingkan di antara 
ketiga-tiga kumpulan rawatan (p-value: 0.00). 17 pesakit (47.2%) di dalam kumpulan 
perawatan tunggu dan lihat (EM), berjaya hamil dalam tempoh 12 bulan. Manakala, di dalam 
kumpulan hiperstimulasi ovary terkawal (COH), 13 pesakit (36.1%) berjaya hamil. Dan di 
dalam kumpulan hiperstimulasi ovari terkawal dan permanian berhadas (COH+IUI), hanya 2 
pesakit (5.4%) berjaya hamil . 
Dalam mengkaji hubungan di antara kesan terhadap ovari dan kadar kehamilan, keputusan 
mendapati bahawa di dalam kumpulan hiperstimulasi ovary terkawal (COH), kadar 
kehamilan adalah lebih tinggi di kalangan pesakit yang mempunyai 1 follicle yang dominan 
(69.2%). Sementara itu, tiada perbezaan kadar kehamilan di anatara pesakit yang 
mempunyai 1 dan 2 follicle yang dominan. Secara keseluruhannya, kadar kehamilan boleh 
ditentukan melalui jumlah follicle yang dominan (p-value=0.01) 
Dalam mengkaji hubungan di antara kesan terhadap lapisan endometrium dan kadar 
kehamilan, keputusan mendapati bahawa, di dalam kumpulan hiperstimulasi ovary terkawal 
(COH), kadar kehamilan adalah lebih tinggi di kalangan pesakit yang mempunyai lapisan 
endometrium 6-10mm (69.2%). Di dalam kumpulan hiperstimulasi ovary terkawal dan 
permanian berhadas (COH+IUI) , tidak ada perbezaan kadar kehamilan di antara pesakit 
yang mempunyai lapisan endometrium 1-5mm dan lapisan endometrium 6-10mm. Secara 
keseluruhan, tahap ketebalan lapisan endometrium bukan merupakan faktor penting dalam 
menentukan kadar kehamilan (p-value=0.55) 
Kajian juga mendapati tiada perbezaan risiko pesakit mengalami masalah sindrom 
hiperstimulasi ovary (OHSS) dan kandungan kembar (multiple pregnancies) di antara ketiga-
tiga kumpulan rawatan 
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KESIMPULAN: Kajian ini mendapati bahawa kesan perawatan tunggu dan lihat (EM) adalah 
setanding dengan hiperstimulasi ovary terkawal (COH) dan hiperstimulasi ovary terkawal 
dan permanian berhadas (COH+IUI) untuk pesakit yang menghadapi masalah 
ketidakhamilan tanpa sebab.  
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ABSTRACT 
A 3 YEAR ANALYSIS OF THE OUTCOME OF VARIOUS TYPES OF MANAGEMENT FOR 
UNEXPLAINED INFERTILITY IN HOSPITAL USM (2010-2013)  
Dr W Fadhlina Binti W Adnan 
MMED Obstetric and Gynaecology 
Department of Obstetric and Gynecology 
School of Medical Sciences, Universiti Sains Malaysia 
Health Campus, 16150 Kelantan, Malaysia 
INTRODUCTION: Unexplained infertility has been shown to be one of the most common 
causes for infertility. Unexplained infertility is diagnosed when there is persistent failure to 
conceive despite basic investigations such as seminal fluid analysis (SFA), tubal patency 
tests and assessment of ovulation showed normal results. There are a number of 
therapeutic approaches used to actively managed unexplained infertility: controlled ovulation 
hyperstimulation (COH) and intrauterine insemination (IUI) and in vitro fertilization (IVF). 
However the best practice in managing couple with unexplained infertility is expectant 
management (EM) which can be considered for up to 3 years, while taking into account the 
women’s age. This study aimed to study the outcome of patients with unexplained infertility 
receiving expectant management (EM) as compared to controlled ovulation hyperstimulation 
(COH) and controlled ovulation hyperstimulation and intrauterine insemination (COH+IUI). 
OBJECTIVE: To evaluate the outcome of patients diagnosed with Unexplained Infertility 
undergoing Expectant Management (EM) compared to Controlled Ovulation 
Hyperstimulation (COH) and Controlled Ovulation Hyperstimulation and Intrauterine 
Insemination (COH+IUI). The primary outcome is the pregnancy rate. The secondary 
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outcomes are the ovarian response and the endometrial response among patients receiving 
stimulated cycles. Apart from that we have also assessed the risk of developing Ovarian 
Hyper-stimulation Syndrome (OHSS) and multiple pregnancy among these patients. 
STUDY DESIGN:  This is a retrospective and prospective cohort study among women with 
unexplained infertility from 1st December  2010 until 30st November 2013, aged 18-44 years 
old undergoing their treatment at Hospital Universiti Sains Malaysia (HUSM). The subjects 
were recruited from the infertility clinic at HUSM. They were given EM, COH or COH+IUI. 
RESULTS: Total of 109 patients was enrolled in this study; 36 patients under EM, 36 
patients under COH and 37 patients under COH+IUI. There were no significant statistical 
differences between the 3 treatment groups, in terms of the socio demographic and 
characteristics of unexplained infertility i.e. age, BMI, ethnicity, husband’s smoking status, 
type of infertility and duration of Infertility. (p-value > 0.05) 
There is a significant difference in terms of pregnancy rate between the 3 treatment groups 
(p-value = 0.00). In EM group, 17 patients (47.22%) managed to conceive within the 12 
months of follow-up. In the COH group, 13 of them (36.1%) managed to conceive using this 
regime .In COH+IUI group 2 of them (5.4%) managed to conceive using this regime, 1 
patient from using CC + IUI and another one from using recombinant FSH +IUI.  
For correlation between ovarian response and pregnancy rate, result showed that patients in 
COH group had higher pregnancy rate with even 1 dominant follicle (69.2%) While in the 
COH+IUI group, the pregnancy rate is similar in patients with 1 dominant follicle and 2 
dominant follicles. As a whole, there is significant correlation between pregnancy rate and 
number of dominant follicles (p-value= 0.01) 
For correlation between endometrial receptivity and pregnancy rate, result showed that 
patients in COH group had higher pregnancy rate when the endometrial thickness is 
between 6-10mm (69.2%). In the COH+IUI group, there is no significant difference seen in 
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terms of pregnancy rate in couples with ET 1-5mm and ET 6-10mm. As a whole, ET is not a 
significant predictor for pregnancy rate for stimulated cycles (p-value=0.55) 
There were no differences between COH and COH+IUI group in terms of risk of developing 
OHSS and rate of multiple pregnancies.  
CONCLUSION: Expectant management is comparable to COH and IUI in the management 
of unexplained infertility in terms of pregnancy rate. 
Assoc Prof Adibah Ibrahim: Supervisor 
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ABSTRAK 
ANALYSIS TENTANG KEBERKESANAN PELBAGAI JENIS PERAWATAN UNTUK 
MASALAH KETIDAKSUBURAN TANPA SEBAB DI HOSPITAL USM UNTUK TEMPOH 3 
TAHUN (2010-2013)  
Dr W Fadhlina Binti W Adnan 
MMED Obstetrik and Ginekologi 
Jabatan Obstetrik and Ginekologi 
Pusat Pengajian Sains Perubatan, Universiti Sains Malaysia 
Kampus Kesihatan, 16150 Kelantan, Malaysia 
PENGENALAN: Penyakit ketidaksuburan tanpa sebab merupakan salah satu penyebab 
kepada masalah inefrtiliti. Ketidaksuburan tanpa sebab ini bermaksud apabila masalah 
infertility ini berterusan walaupun kajian dasar seperti ujian air mani, ujian ketelusan salur 
fallopian dan ujian kesuburan adalah normal. Ada beberapa cara yang digunakan untuk 
merawati masalah ini secara aktif; hiperstimulasi ovary terkawal (COH) dan permanian 
berhadas (IUI) dan perawatan tabung uji (IVF). Namun, kaedah perawatan yang terbaik 
untuk pesakit yang menghadapi masalah ini adalah kaedah tunggu dan lihat yang boleh 
diguna untuk tempoh 3 tahun, dengan mengambil kira umur ibu. Kajian ini bertujuan melihat 
keberkesanan perawatan yang diberikan kepada pesakit menghidapi masalah 
ketidaksuburan tanpa sebab ini; kaedah tunggu dan lihat (EM), kaedah hiperstimulasi ovary 
terkawal (COH) dan kaedah hiperstimulasi ovary terkawal dan permanian berhadas 
(COH+IUI). 
 
V 
 
OBJEKTIF: Untuk mengkaji keberkesanan perawatan tunggu dan lihat (Expectant 
Management (EM)) terhadap pesakit yang menghadapi masalah ketidaksuburan tanpa 
sebab, berbanding dengan pesakit yang menggunakan rawatan hiperstimulasi ovary 
terkawal (Controlled Ovulation Hyperstimulation (COH)) dan hiperstimulasi ovary terkawal 
dan permanian berhadas (Controlled Ovulation Hyperstimulation and Intrauterine 
Insemination (COH+IUI)). Kesan utama yang dikaji adalah kadar kehamilan. Kesan 
sampingan yang dikaji adalah kesan terhadap ovari dan kesan terhadap lapisan 
endometrium bagi pesakit yang mendapat perawatan hiperstimulasi ovary terkawal (COH) 
dan hiperstimulasi ovary terkawal dan permanian berhadas (COH+IUI). Selain daripada itu 
kami juga mengkaji kadar kesan sampingan seperti sindrom hiperstimulasi ovari (Ovarian 
Hyperstimulation Syndrome (OHSS)) dan kandungan kembar (Multiple Pregnancies). 
KAEDAH KAJIAN:  Ini adalah merupakan kajian retrospektif dan prospektif terhadap 
pesakit yang mengalami masalah ketidaksuburan tanpa sebab dari 1hb Disember 2010 
sehingga 31hb November 2013, berusia 18-40 tahun, yang mendapat perawatan di Klinik 
Infertilti, HUSM. Mereka telah dibahagikan di dalam 3 kumpulan berdasarkan rawatan yang 
diterima, perawatan tunggu dan lihat (EM), hiperstimulasi ovary terkawal (COH) dan 
hiperstimulasi ovary terkawal dan permanian berhadas (COH+IUI). 
KEPUTUSAN: Seramai 109 orang pesakit telah menyertai kajian ini, 36 pesakit dalam 
kumpulan perawatan tunggu dan lihat (EM), 36 pesakit dalam kumpulan hiperstimulasi ovary 
terkawal (COH) dan 37 pesakit dalam kumpulan hiperstimulasi ovari terkawal dan 
permanian berhadas (COH+ IUI). Kajian tidak mendapati sebarang perbezaan ketara dalam 
kadar kehamilan berdasarkan faktor sosio demografik dan ciri-ciri ketidaksuburan tanpa 
sebab seperti umur pesakit wanita, “body mass index [BMI]”, kumpulan etnik, status 
merokok dikalangan suami, jenis infertiliti dan tempoh ketidaksuburan. 
Kajian menunjukkan perbezaan ketara dalam kadar kehamilan jika dibandingkan di antara 
ketiga-tiga kumpulan rawatan (p-value: 0.00). 17 pesakit (47.2%) di dalam kumpulan 
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perawatan tunggu dan lihat (EM), berjaya hamil dalam tempoh 12 bulan. Manakala, di dalam 
kumpulan hiperstimulasi ovary terkawal (COH), 13 pesakit (36.1%) berjaya hamil. Dan di 
dalam kumpulan hiperstimulasi ovari terkawal dan permanian berhadas (COH+IUI), hanya 2 
pesakit (5.4%) berjaya hamil . 
Dalam mengkaji hubungan di antara kesan terhadap ovari dan kadar kehamilan, keputusan 
mendapati bahawa di dalam kumpulan hiperstimulasi ovary terkawal (COH), kadar 
kehamilan adalah lebih tinggi di kalangan pesakit yang mempunyai 1 follicle yang dominan 
(69.2%). Sementara itu, tiada perbezaan kadar kehamilan di anatara pesakit yang 
mempunyai 1 dan 2 follicle yang dominan. Secara keseluruhannya, kadar kehamilan boleh 
ditentukan melalui jumlah follicle yang dominan (p-value=0.01) 
Dalam mengkaji hubungan di antara kesan terhadap lapisan endometrium dan kadar 
kehamilan, keputusan mendapati bahawa, di dalam kumpulan hiperstimulasi ovary terkawal 
(COH), kadar kehamilan adalah lebih tinggi di kalangan pesakit yang mempunyai lapisan 
endometrium 6-10mm (69.2%). Di dalam kumpulan hiperstimulasi ovary terkawal dan 
permanian berhadas (COH+IUI) , tidak ada perbezaan kadar kehamilan di antara pesakit 
yang mempunyai lapisan endometrium 1-5mm dan lapisan endometrium 6-10mm. Secara 
keseluruhan, tahap ketebalan lapisan endometrium bukan merupakan faktor penting dalam 
menentukan kadar kehamilan (p-value=0.55) 
Kajian juga mendapati tiada perbezaan risiko pesakit mengalami masalah sindrom 
hiperstimulasi ovary (OHSS) dan kandungan kembar (multiple pregnancies) di antara ketiga-
tiga kumpulan rawatan 
KESIMPULAN: Kajian ini mendapati bahawa kesan perawatan tunggu dan lihat (EM) adalah 
setanding dengan hiperstimulasi ovary terkawal (COH) dan hiperstimulasi ovary terkawal 
dan permanian berhadas (COH+IUI) untuk pesakit yang menghadapi masalah 
ketidakhamilan tanpa sebab.  
Prof Madya Adibah Ibrahim: Penyelia 
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1.0 INTRODUCTION 
Infertility is defined as failure to conceive after regular unprotected sexual intercourse for 2 
years. Infertility affects 80 million couples worldwide (Vayena et al 2002). In UK it is 
estimated that 1 in 7 couples suffers from infertility.  In Malaysia alone, the Ministry of Health 
estimates that 10-15% of couples suffered from infertility, a figure similar to most developing 
countries. Recent estimates put the figure about 300,000 couples in Malaysia. 
It appears that there has been no major change in the prevalence of infertility in recent 
years, however the numbers have shown that more couples are seeking medical attention 
than previously (RCOG, 1999).  Boivin et al 2007 estimated that 50% couples have sought 
medical assistance for infertility. 
A district health authority may see around 230 new referrals each year for infertility concern 
(RCOG, 1999). In Malaysia, the Ministry of Health estimate that infertility accounts for 15-
20% of gynaecology patients in our hospital.  
Hospital USM has established itself as one of the secondary/tertiary centre offering infertility 
service in the East Coast Malaysia for at least more than 10 years. It is therefore justified the 
need to evaluate the effectiveness of the treatment provided to our patients and provide 
database on our services for future research and treatment protocol. 
There was a variety distribution of causative factors of infertility in different communities. In 
UK, causes of primary infertility are male factor (30%), unexplained infertility (25%), female 
factor which include ovulatory disorders, tubal disease and uterine or peritoneal cause 
(45%). In 20% of cases, the male and female factors co-exists. 
A local study which was done at Hospital Sultanah Bahiyyah, Alor Setar, Kedah showed that 
causes of infertility are ovulatory dysfunction (46%), unexplained (22%), mixed (13%) , male 
(6%), tubal (5%), cervical (3%) and others (5%).  
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Unexplained infertility has been shown to be one of the most common causes for infertility, 
which we choose to evaluate in our study. Unexplained infertility is diagnosed when there is 
persistent failure to conceive despite basic investigations such as seminal fluid analysis 
(SFA), tubal patency tests and assessment of ovulation showed normal results. 
Some studies have shown the prevalence can be as high as 60% in certain centres 
(Templeton & Penney et al, 1982). Meanwhile, the reported incidence of unexplained 
infertility has also been shown to be varied between different studies based on the age and 
selection criteria (Aboulghar et al 2003, Isaksson & Tiitinen, 2004). In the study, we 
assessed their socio demographic criteria to determine the characteristics of couples with 
unexplained infertility among our population. 
The decision to treat patients with unexplained infertility would depend on the female’s age, 
the duration of infertility and the type of infertility (i.e. primary and secondary infertility) (Hull 
et a,l 1985, Lenton et al, 1977).  
Female’s age is the most important factor that influences a couples’ fertility.  
Table 1: The Percentage Women become childless based on Maternal Age 
Adapted from Menken J et al 1986  
Table 1 showed that female fertility reduces with age. Women aged >35 years old, has 
increased rate of remain childless ≥ 30 %. Even when regular sexual intercourse, 94% of 
fertile women aged 35 years and reduced to 77% of those aged 38 years will conceive after 
3 years of trying (NICE Cllinical Guidelines, 2004). 
Age of women at which started to try to conceive (years) Remain childless (%) 
20-40 6 
25-29 10 
30-34 15 
35-39 30 
40-44 >60 
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Studies have shown that there is a correlation between the female’s age and the number of 
antral follicles in women with infertility. Castro et al 2012 showed a linear pattern of decline 
in antral follicle count (AFC) with age in all percentiles. 
There is also a correlation between increased in chromosomal errors with advanced 
maternal age. This is supported by increase in spontaneous abortion and chromosomal 
abnormalities in babies born to mothers with old age (Hook EB et al, 1983, Munne S et al, 
1994) 
An advancing age of a women may give effect on the treatment result and a lowered natural 
fecundity and increase in spontaneous abortion rate (30% at age 40 years old) must be 
taken into account when counselling is given to women age over 35 years old. 
Duration of infertility is another important factor in determining the treatment plan. Studies 
have shown many couples with unexplained infertility will have spontaneous conception and 
have a live birth without treatment 92-4% per menstrual cycle).  Pregnancy rate in 1 year is 
15%, 35% in 2 years and 80% in 3 years (Isaksson & Tiitinen, 1998, Hull et al, 1985, 
Guzick et al, 1998). This shows that women with longer duration of infertility, their chance to 
conceive reduced.  
As shown in Table 2, the chance of a women to conceive increases with the increasing 
number of months trying. However, there is a drastic fall in the chance to conceive after two 
years of trying.   
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Table 2: The Chance for Spontaneous Conception based on duration 
Duration of trying (months) Chances for spontaneous conception (%) 
1 20 
6 70 
12 85 
18 90 
24 95 
36 40 
48 4 
Adapted from Quick Guideline to the Management of Infertility (USM), 2011 
Infertility can be categorised based on Primary and Secondary Infertility. Primary infertility 
refers to couple who have not become pregnant after at least 1 year of unprotected sexual 
intercourse. Secondary infertility refers to couple who have been pregnant previously 
regardless of the outcome (World Health Organisation). Studies have shown that couples 
with secondary infertility are more commonly associated with successful spontaneous 
pregnancy compared to couples with primary infertility. 
The best practice in managing couples with unexplained infertility is expectant management 
(EM) which include advice on lifestyle and successful conception. Expectant management 
(EM) for up to 3 years can be considered, taking into account the women’s age. However 
expectant management is not attractive to couples with unexplained infertility and even 
clinicians, as most would prefer an active management. 
A number of therapeutic approaches have been used to actively manage unexplained 
infertility: Controlled Ovulation Hyperstimulation (COH), Intrauterine Insemination (IUI) and In 
Vitro Fertilisation (IVF). Ovarian hyperstimulation with IUI is effective although IVF is more 
preferred.  
5 
 
Fertility treatments are costly. In this case IVF treatment which can cost approximately US 
Dollar 33,000 – 41,000 in UK, US and Canada. Total ART treatment costs as percentage of 
total healthcare expenditures in 2003 were 0.06% in US (Connolly M. P et al 2010). 
The funding structure for IVF/ART is highly variable among different nations. In US there is 
no federal government assistance exists for IVF. Many other countries provide full or partial 
coverage thru government insurance. In Malaysia there are over 40 IVF centres available 
and the cost is expensive i.e. RM 12,000 – 18,000 per cycle. Thus, we need to counselled 
and tailored treatment specifically for each patient, based on the above factors. 
This aim for this retrospective and prospective study is to evaluate the treatment and 
outcome of patients with unexplained infertility treated in our infertility clinic, in order to find 
an optimum method in treating such cases. 
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2.0 LITERATURE REVIEW 
2.1 Aetiology of Infertility 
The causes of infertility can be divided into male factor (35%), female factor (50%) and 
unexplained infertility (15%). Of the female factor, it is further divided into ovulatory 
disorders, tubal factors, uterine factor and endometriosis associated infertility. 
A retrospective audit by De M et al, 2005 followed up the management and outcome of 
patients referred to a specialist infertility clinic for 4 years duration. 179 couples were 
included in the study. Results showed the causes of infertility were unexplained infertility 
(17.5%), tubal factor (27%), anovulation Infertility (21%), male factor (17.5%), multi-factorial 
(8%), endometriosis (3%) and congenital factors (3%).  
In another study by Wilkes S. et al, 2009 did a population based study in UK primary care 
looking into the epidemiology and management of infertility. They aim to describe the 
incidence, prevalence, referral patterns and outcomes of infertile couples. The diagnoses of 
infertility are unexplained infertility (38%), ovulation dysfunction (25%), semen disorder 
(25%) and tubal factor (18%). 
Male factor infertility is not a rare problem. It affects 1 in 20 men. The aetiologies of male 
factor infertility are disorders of spermatogenesis, duct obstruction, accessory gland 
disorders, disorders of sperm and vesicular fluids, sexual dysfunction and psychological and 
environmental factors. Despite these, in the majority of cases, the cause of male infertility is 
unknown. Recent studies are now focusing of epigenetic factors causing male factor 
infertility (Dada R et al, 2012). 
IUI may be considered as the first line treatment in male infertility. If pregnancy is not 
achieved after 3-6 cycles of IUI, IVF can be proposed (Tournaye H. et al, 2012) 
Ovulatory disorder is the principal cause of female infertility, contributing about 1/5th of all 
infertile couple (Ashalatha S et al, 2000). Ovulation disorders can be divided into 3 groups 
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based on WHO Classification of Ovulatory Disorders. The treatment would depend on the 
group of disease.  
WHO Group 1 Ovulation Disorder showed a hypogonadotrophic hypogonadism e.g. Kallman 
syndrome. Patients in this group would responds to treatment with injections of 
gonadotrophin releasing hormone (GnRH) or gonadotrophin formulation containing 
leiutenizing hormone (LH). 
WHO Group 2 Ovulation Disorder is also known as hypothalamic pituitary dysfunction. 
Example is Polycystic Ovarian Syndrome (PCOS), which has a prevalence rate of 4-18%. 
Women in this group can be treated using ovulation induction agents such as clomiphene 
citrate, metformin and gonadotrophins. 
Meanwhile, women in Group 3 Ovulation Disorders which is also known as 
hypergonadotrophic anovulation or ovarian failure, has very low chance to conceive 
spontaneously. IVF with oocyte donation remains the mainstay treatment for these women. 
Tubal factor infertility causes 14% of cases of infertility, with pelvic inflammatory disease 
(PID) being the most common cause. Other causes include septic abortion, ruptured 
appendix, pelvic surgery and ectopic pregnancy. 75% of cases of tubal disease involved the 
distal part and 25% of cases are of proximal part. 
Patients with proximal tubal blockage can be offered selective salphingography and tubal 
catheterization under x-ray. This may improve pregnancy rate. However if the procedure 
failed, patient can be considered for tubo-cornual anastomosis, which can increase 
pregnancy rate up to 50% if done by trained surgeon. 
Patients with distal tubal blockage, can be offered microsurgical approach using 
magnification. The pregnancy rate would depends on the degree of the disease; pregnancy 
rate is higher in couples with mild peri-tubal adhesion compared to patients with gross 
hydrosalphinx. In couple with moderate to severe tubal disease, we should offer IVF. 
8 
 
Uterine factor causes 15% of couples with infertility. Fibroid is the most common cause of 
uterine factor related infertility, and others are endometrial polyp, intrauterine adhesions and 
structural abnormalities.  
The interference of fibroid on infertility is largely depends on their location. Submucosal 
fibroid would  interfere with implantation, and thus should be removed regardless of the size 
and structure. intramural fibroid distorting the endometrial cavity can reduce conception rate 
and can be removed. There is no evidence to support the removal of  subserosal fibroid in 
asymptomatic women. Myomectomy can be done hysteroscopically or abdominally 
(Gambadauro P et al, 2012). 
Endometriosis which is characterised by presence of glandular epithelial and stromal cells in 
the extra uterine environment, affects 10-15% of women in the reproductive age. The 
disease affects several parts in the women reproductive system i.e. ovarian function, 
oocycte retrieval, embryo development and the endocrine system involved in the 
reproductive process and results in infertility and pregnancy loss (Stilley J A  et al, 2012). 
Endometriosis is classified using the American Fertility Society (AFS) system of 
Classification and the management would depends on the stages of endometriosis. In 
minimal to mild endometriosis, medical treatment do not enhance pregnancy rate. Ovarian 
hyperstimulation and intrauterine insemination (IUI) is more effective than no treatment. 
Surgical ablation have not been shown to improve fertility. 
In moderate to severe endometriosis, studies have not shown that medical treatment either 
alone or with surgery improves fertility. On the other hand, surgical management (which 
include cystectomy or drainage of cyst) can be beneficial at this stage. 
Unexplained infertility is diagnosed when standard investigations which include semen fluid 
analysis (SFA), tubal patency tests and ovulation assessment, failed to identify any 
abnormalities or provide a diagnosis. 
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Most centres would investigate these couples extensively in an effort to find the cause for 
their failure of conception. In a prospective study of 114 women diagnosed with 
unexplained infertility, done by Bonneau C et al, 2012 showed that laparoscopy 
revealed pelvic pathology in 95 patients. Thus diagnostic laparoscopy should be 
strongly considered in unexplained infertility workup should not be underestimated  
Fatini C et al, 2012 tried to demonstrates the relationship between inherited thrombophilia 
and unexplained infertility thus suggesting the contribution of genetic components in 
modulating unexplained infertility, behind anovulation, male and tubal factor. Another recent 
development is seen in Kokcu A et al, 2012 made a synthesis and review of literature 
looking into possible roles of various immunological factors in recurrent miscarriages and 
unexplained infertility. 
Haxton M J et al, 1987 has showed that there is no evidence that the approach of doing 
extensive research is superior to waiting for spontaneous conception which is concurred with 
solid epidemiological evidence.  
2.2 Investigations of Infertility 
The general consensus is that infertile couple should be investigated as soon as they seek 
medical attention. However the decision on detail and urgent investigations will vary 
depending on several factors such as duration of infertility and maternal age (Obstetrics, 
Gynaecology and Reproductive Medicine 2007). 
According to the guideline, both husband and wife should be directly involved in the 
management of their infertility problems. Thus it is generally agreed that both couple need to 
be seen together, which is describe as couple centred management, as decisions taken on 
each other’s partner will affect both of them (NICE Clinical Guidelines 2004). 
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For investigations and management of infertility, physician would generally adhere to the 
Royal College of Obstetricians and Gynaecologists Evidence-based Clinical 
Guidelines on Initial Investigations and Management of the infertile couple (1999).  
Detailed history need to be taken from both husband and wife, including menstrual history, 
sexual history, past medical illness and past surgical history, family history and social 
history.  
Drug history including drug abuse on both partners should also be elicited. Environmental 
factors and occupation of the patients can also affect infertility. (Quick Guideline in 
Management of Infertility in USM 2011) 
Clinical evaluation of the infertile couple should include 5 categories: Seminal Fluid Analysis 
(SFA), Post coital test, Assessment of ovulation, uterine and tubal evaluation and 
Laparoscopy (Balasch et al, 2000). Of these, SFA, mid luteal phase progesterone and tubal 
patency evaluation comprises the initial basic patient work up (Crosignani and Rubin 
2000). And in patients with unexplained infertility, all the results expected to be normal. 
RCOG suggested that male partner should have two SFA done during the initial 
investigations.  A single SFA will be able to identify almost 90% of men with true semen 
abnormalities. However, if abnormalities detected, a second confirmatory test after 3 months 
would increase its specificity. 
For semen collection, the RCOG suggested abstinence for 2-3 days prior to the test. The 
male partner is suggested to produce the sample by masturbation and not by coitus 
interruptus. They are advised to use a wide mouth sterile plastic specimen cup and not to 
use condom when collecting the specimen. When delivering the specimen, they are to bring 
the specimen to the laboratory as quickly as possible and to keep at body temperature. 
Medical practitioners are advised to use the same laboratory, as different ones might have 
different criteria. Although many laboratory would adhere to WHO values for normal SFA. 
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Normal semen volume is 2-5ml. Liquefication time is within 30 minutes. Semen 
concentration should be > 20 million/ml, with semen motility of > 50%, semen morphology > 
30% normal forms and WBC < 1 million/ml. 
The ovarian reserve is assessed the remaining population of primordial and resting follicles 
(Gougeon et al, 1986).  There are several methods in evaluating the ovarian reserve such 
as serum FSH and LH, oestradiol (E2) levels, progesterone levels, Inhibin B, antral follicle 
count and serum Anti- Mullerian Hormone (AMH) however, only antral follicle count and 
early follicular phase FSH are the most common test and used in this study to assess 
ovarian reserve. 
Assessing ovulation is part of investigations in couples with infertility. Women with regular 
menstrual cycle are generally ovulating. There are several methods used in assessing 
ovulation, such as basal body temperature, urinary measurement of LH surge, mid luteal 
phase serum progesterone and ultrasound scan. However, only these last two are generally 
used. 
Assessing tubal patency is part of investigations for patients with infertility. There are 2 most 
common ways to assess for tubal patency; hysterosalphingogram (HSG) and laparoscopic 
dye insufflation test. To choose which test to perform for each particular patient, the RCOG 
recommended the use of HSG in low risk couples and laparoscopy if pelvic assessment is 
indicated or if HSG shows tubal damage. Other tests include hystero-contrast-sonography, 
selective salphingography or fertiloscopy and falloposcopy.  
Couples with unexplained infertility would have normal results shown on all the above 
investigations. 
2.3 Management of Unexplained Infertility 
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It is generally accepted that unexplained infertility can be managed either by expectant 
management (EM), controlled ovulation hyperstimulation (COH) or controlled ovulation 
hyperstimulation + intrauterine insemination (COH+IUI) and in vitro fertilisation (IVF). 
Although Ray A et al, 2012 wrote an update and review of practice for unexplained infertility 
in the Reproductive Biomed Online Journal. The research team concluded that treatment for 
unexplained infertility is empirical and many different regimens have been used. The 
standard protocol has been to progress from low technology to high technology treatment 
options. However more multicentre RCT is needed to identify the best treatment option in 
unexplained infertility. 
2.3.1 Expectant Management (EM) 
Expectant management would substitute as medical practitioner giving general advice 
regarding lifestyle issues such as diet, exercise, smoking and sexual intercourse. Patients 
are advised to take folic acid 0.4mg daily as supplements to prevent neural tube defect. 
Patients may be provided with appropriate evidence based information, verbal and written in 
a format they understand during consultation (NICE Clinical Guidelines 2004). 
Period of expectant management are usually given for 6-12 months duration, and during this 
period they are no clinical visits or medical intervention done. They are either given date 
after specified time for assessment and further treatment, or sometimes advised to return 
back if they fail to conceive. 
However, as expected, this type of management is not attractive and popular among 
patients and even medical practitioner, and they would thus resort to other methods most 
commonly controlled ovulation hyperstimulation (COH) and controlled ovulation 
hyperstimulation + intrauterine insemination (COH+IUI). 
Previous studies have compared between expectant management (EM) and controlled 
Ovulation Hyperstimulation (COH) with intrauterine insemination (IUI) whether stimulated or 
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non-stimulated cycles. These studies have aimed to prove that in correct patient selection, 
expectant management is not inferior to other available treatment. 
Example of such study is a famous study by Bhattacharya S et al in 2008 which compared 
the effectiveness of clomiphene citrate and unstimulated intrauterine insemination with 
expectant management for the treatment of unexplained infertility. The result from the study 
showed that empirical clomiphene citrate and unstimulated intra uterine insemination are 
unlikely to offer superior live birth rates, when compared to expectant management. 
Other studies such as Custers I M et al in 2011 has shown that in couples with unexplained 
infertility, initial expectant management (EM) for 6 months is considered cost saving without 
the risk of delay in achieving pregnancy or reduce pregnancy chance. 
Interestingly, a study by Eijkemans M J C et al, 2008 looked into pregnancy chances on 
couples in IVF/ICSI waiting list. The result showed that a chance for ongoing pregnancy 
without treatment while waiting for IVF/ICSI is below 10% but maybe as high as 25% within 1 
year in selected patients,  and more significantly in couples with unexplained infertility 
compared to other causes. 
Woodsworth S et al, 2011 researched on whether clomiphene citrate and IUI are cost 
effective as first line treatment for unexplained infertility. 580 women across 5 Scottish 
hospitals were randomized to 3 groups: expectant management, clomiphene citrate or IUI for 
6 months. The study found that empirical clomiphene citrate and unstimulated IUI do not 
offer superior live birth rates compared to expectant management, despite being more 
expensive. Another study by Brandes M et al, 2011 also recommended that expectant 
management in couples with good pregnancy prognosis.  
Based on evidence above, we evaluated the current treatment for unexplained infertility used 
in our centre (COH and COH+IUI) with expectant management in terms of pregnancy rate, 
and prove that expectant management is comparable to other known treatment modalities in 
the treatment of unexplained infertility. 
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2.3.2 Controlled Ovulation Hyperstimulation (COH) 
Controlled ovulation hyperstimulation using clomiphene citrate has long been considered as 
the first line treatment for couples with unexplained infertility. COH aim is to produce multi 
follicular development and thus increases the pregnancy rate. There several type of 
ovulation induction agents and can be used either individually or in combination. 
Clomiphene citrate was first successfully used as ovulation induction agent in 1961. It is the 
most commonly used drug in patients with WHO group 2 ovulation disorders and has been 
used empirically for patients with unexplained infertility. 
Clomiphene citrate is a non-steroidal selective oestrogen receptor modulator which acts 
primarily by binding with oestrogen receptors at the hypothalamus. This competitive 
inhibition results in a perceived drop of circulating oestrogen to the hypothalamus, thus 
eventually lead to increase in gonadotropins secretion and subsequent induction of 
ovulation. 
Treatment is usually started with the lowest dose which can achieve ovulation. Clomiphene 
citrate has shown to achieve ovulation rate for up to 80% per cycle with increase in of 20-
25% per ovulatory cycle.  
The reason for its popularity among patients and medical practitioners is because it is 
relatively cheap, requires minimal monitoring and the belief that it is able to correct subtle 
ovulatory dysfunction. 
Patients should be informed regarding the risk of multiple pregnancy and potential risk of 
ovarian cancer. However, we weigh the risks, costs and benefit of this drug, 
Patients who received clomiphene citrate 200mg to 250mg for 5 days for 3-4 cycles without 
response, are diagnosed to have clomiphene resistant. Other ovulation induction drugs are 
used when this occurred.  
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As mentioned above, study that compared between the effectiveness of clomiphene citrate 
when compared to expectant management in the treatment of unexplained infertility has 
shown that there is no significant difference between the two treatment modalities in terms of 
pregnancy rate and live birth rate (Bhattacharya S et al, 2008) 
Several studies have been performed over the years, comparing between clomiphene citrate 
and other types of ovulation induction agents such as aromatase inhibitors for example 
letrazole and anastrazole. So far, there are no known studies that compare between 
clomiphene citrate and gonadotrophins in controlled ovulation hyperstimulation.  
Letrazole is a 3rd generation selective aromatase inhibitor. Letrazole inhibit peripheral 
oestrogen production thus stimulating the release of FSH. It is has been used as ovulation 
induction agents since late 1990s and used in clomiphene-resistant anovulatory patients.  
NICE Guideline Development Group did not recommended the use of aromatase inhibitors 
cannot be in women with unexplained infertility as there are ongoing trial on its safety. 
A randomised controlled trial was conducted at Ain Shams University Hospital and Dar Al 
Hekma Hospital for 2 years duration by Ibrahim M I et al, 2012 comparing between letrazole 
and clomiphene citrate for superovulation in couple with unexplained infertility. There were 
several outcomes measured in this study such as number of mature follicles, serum 
oestradiol level, endometrial receptivity, day of hCG injection and clinical pregnancy 
including the side effects from each treatment group. The study concluded that letrazole has 
beneficial effect on the endometrium, thus may improve implantation rate and pregnancy 
rate.  
Badaway A et al, 2009 has shown that there is no significant difference between 
clomiphene citrate and letrazole, in terms of live birth rate, but no significant difference in 
clinical pregnancy and multiple pregnancy. 
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2.3.3 Controlled Ovulation Hyperstimulation + Intrauterine 
Insemination (COH+IUI) 
Intrauterine insemination has been known to enhance pregnancy rate by three-folds even 
without controlled ovulation hyperstimulation (Hughes E G et al, 1997). IUI is a well-known 
method for assisted reproductive technique. It is a therapeutic treatment. There is a wide 
variation in indications, protocol of ovarian hyperstimulation, semen preparation, timing and 
technique for insemination. 
IUI is indicated in patients with unexplained infertility, prolonged subfertility, cervical factor 
infertility, Stage I/II endometriosis and patient with single fallopian tube. IUI is contra 
indicated in patients with ovarian failure, significant male factor infertility, significant tubal 
adhesions, tubal dysfunction and significant uterine abnormality. 
Controlled Ovulation Hyperstimulation in IUI can be given using clomiphene citrate, 
gonadotrophins or sequential therapy. 
Currently there are various FSH containing products available. FSH containing 
gonadotrophin can be divided into 4 groups: human menopausal gonadotrophin (hMG) 
containing both FSH and LH, Urinary FSH (uFSH), highly purified urinary FSH (uFSH-HP) 
and recombinant FSH (rFSH).  
The human recombinant FSH which is most commonly used in the study is produced from 
Chinese hamster ovary cell line transfected with genes for the α and β subunits of FSH. It 
has subtle differences with the native molecule in its glycosylation and sialation. 
hCG, which has similar structural and biological similarity to LH, is used in combination with 
exogenous gonadotrohin which causes LH surge, and thus induce ovulation once follicle 
development reaches maturity. There are different types of hCG available, but the most 
commonly used in the study is recombinant hCG e.g. Ovidrel, Pregnil. 
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There are 2 regimes used using exogenous gonadotrophin, which are the Step-up Regime 
and the Step-down regime. 
The Step-up regime is the most commonly used in the study. It begins with using a low dose 
exogenous gonadotrophin, 50-75 IU on Day 3-5 of menstrual cycle. It is designed to define 
the effective threshold of response. 4-7 days after stimulation, treatment response is 
measured using TVS and or serum oestradiol level.  
Response is labelled as adequate response when there is increase in the growth of one or 
two follicles and or a moderate rise in serum oestradiol level. We need to increase the dose 
of exogenous gonadotrophin by 37.5-75 IU when there is inadequate response. The dose in 
maintained or increased as indicated. TVS is done to assess the number and size of follicles 
every 1-2 days. Most of the COH cycle would take 7-12 days. 
Once the dominant follicle (DF) is more than 12 mm and the endometrial thickness is more 
than 10, hCG injection is given to induce ovulation. If there is signs of ovulation 
hyperstimulation (OHSS) or more than 3 follicles with 17mm size, or more than 4-5 follicles 
with 14mm size, hCG injection is withhold.   
In contrast, the Step-down regime started with a higher dose (150-225iu) and the dose a 
gradually reduced. The aim is to promote continued development of the more sensitive 
dominant follicle only and withdraw its support from the less sensitive smaller follicles. 
This type of regime is usually used after the response threshold has been established in one 
or more previous stimulation cycle.  
Sequential treatment is a treatment regime that has been used in patients with clomiphene-
resistant anovulatory cycle and in patients with unexplained infertility.  The regime would be 
commenced with a standard course of clomiphene citrate using either 50 or 100 mg daily 
dose from Day 2- Day 6 cycles. This is followed by a low dose hMG/rFSH 75iu daily 
beginning on the last day of clomiphene citrate.  
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The monitoring of response from this treatment regime is similar to the exogenous 
gonadotrophin regime. The pregnancy rate is found to be almost similar to exogenous 
gonadotrophin, with an added advantage of using lower dose of gonadotrophin, shorter 
duration of gonadotrophin use and thus the cost is lower. 
Sperm washing would allow selection of sperm with normal morphology, motility and 
absence of antibody, WBC and infectious organism. Preferred sperm preparations are the 
one yielding the largest population of highly motile cells without chemical or cellular 
component. The most commonly used methods are standard swim up regime and density 
gradient prep. 
IUI is performed on the day when the postulated follicle will rupture, thus increases the 
chance to pregnancy. This is estimated 24 hours after spontaneous ovulation, 34-36 hours 
after hCG injection in induced ovulation. 
The sperm must be available at least 1 hour before insemination for preparation. 0.5 - 3ml of 
washed or prepared sperm is introduced into the uterine cavity by means of a thin cannula. 
Post IUI procedure, patients are given progesterone tablet for luteal support. 
2.3.3.1 Studies Compare between Clomiphene citrate and 
Gonadotrophins 
Berker B et al, 2011 performed a randomized trial comparing the efficacy between 
recombinant FSH and clomiphene citrate for ovarian stimulation in couples with unexplained 
infertility and male subfertility undergoing IUI. 198 couples were treated with 100 mg/day 
clomiphene citrate for 5 days (93 patients) or recombinant FSH with starting dose of 75–100 
IU daily (96 patients).  
The main outcome measurement was on-going pregnancy rate (OPR). Continuous variables 
were compared with student’s t test or Mann–Whitney U test according to distribution of 
each variable. Categorical variables were compared with Chi square test or Fisher’s exact 
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test where appropriate. The study concluded that recombinant FSH is superior to 
clomiphene citrate for enabling multi-follicular development in COH+IUI cycles of 
unexplained and male infertility couples.  
Nayar K D et al, 2008 conducted a study comparing the efficacy between clomiphene citrate 
and low dose recombinant FSH for ovarian hyperstimulation in IUI cycles for unexplained 
infertility and male subfertility. This prospective cohort study was done from January 2007 to 
September 2007. The outcome measured was: Clinical pregnancy rate, multiple pregnancies 
and spontaneous abortion. Results were analysed following the intention–to-treat principle.  
Cumulative pregnancy rates (17.33% vs. 20.0%; relative risk [RR], 0.839; 95 % confidence 
interval [CI], 0.363 to 1.937) were similar between two groups. Spontaneous abortion rate 
and multiple pregnancy rate were similar between two groups. There is no significant 
difference of pregnancy rates (p<0.68), spontaneous abortion (p<0.931) and multiple 
pregnancies (p<0.812) between two groups (p>0.05).  
The study concluded that in couples with primary unexplained or male subfertility 
participating in an IUI program, ovarian hyperstimulation can be achieved by CC or rFSH. No 
significant difference in pregnancy rates between CC and rFSH was observed. 
2.3.3.2 Studies Compare between Doses of Gonadotrohpins 
A prospective study were done by Streda R et al  in 2012 trying to compare between 
different starting gonadotrophin doses for ovulation induction in combination with IUI. The 
patients were divided into 50, 75 and 100 IU group based on patients’ response to 
clomiphene citrate treatment. The results showed that all treatment regimes were effective 
for ovulation induction. They reported on the case of multiple pregnancy, but not on the 
incidence of OHSS. 
2.3.3.3 Studies Compare between Stimulated and Unstimulated IUI 
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Goverde A J et al, 2005 compared between natural and mild hyperstimulation cycles for IUI, 
their effects on pregnancy and multiple pregnancy. Pregnancy outcome of 310 natural and 
334 mildly hyperstimulated cycles for IUI in 171 couples with unexplained or mild male factor 
subfertility was analysed on a patient level with random coefficient models.  
Results showed that the pregnancy rates were similar; 35% and 39.8% per couple in the 
natural and mildly hyperstimulated cycles respectively (p-value = 0.60). Multiple 
pregnancies, all twin pregnancies, were conceived significantly more frequently in the mild 
hyperstimulation group (27% of the pregnancies) than in the natural cycle group (4% of the 
pregnancies) (p-value = 0.01).  
The application of a mild hyperstimulation protocol as an alternative to a standard 
hyperstimulation protocol for IUI does not result in higher pregnancy rates than IUI in the 
natural cycle, while at the same time multiple pregnancies cannot be avoided. 
2.3.3.4 Studies Compare between Stimulated IUI using Clomiphene 
citrate and Gonadotrophin 
A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for 
ovarian hyperstimulation in IUI cycles for unexplained and male subfertility was performed by 
Dankert T et al, 2007. Couples with primary unexplained or male subfertility were 
randomized to receive clomiphene citrate or recombinant FSH for ovarian hyperstimulation. 
Cumulative pregnancy rates and live birth rates were primary outcomes.  
27 pregnancies were observed in the clomiphene citrate group (38%) and 23 in the 
recombinant FSH group (34.3%). The live birth rate was 28.2% (20/71) and 26.9% (18/67) 
for clomiphene citrate and recombinant FSH, respectively. Overall, the live birth rates per 
cycle were 10% for clomiphene citrate-stimulated and 8.7% for recombinant FSH stimulated 
cycles. In couples with primary unexplained or male subfertility participating in an IUI 
program, ovarian hyperstimulation can be achieved by clomiphene citrate or recombinant 
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FSH. No significant difference in live birth rates between clomiphene citrate and recombinant 
FSH was observed.  
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3.0 OBJECTIVES 
3.1 General Objective 
 
To evaluate the outcome of various types of management of unexplained infertility 
3.2 Specific objectives 
1. To determine the demographics of couples with unexplained infertility in Hospital 
USM 
2. To determine the pregnancy rate among patients with unexplained infertility, who 
received expectant management, controlled ovarian hyperstimulation and controlled 
ovarian hyperstimulation with intrauterine insemination 
3. To evaluate the ovarian response and the endometrial receptivity among patients 
receiving stimulated cycles 
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4.0 METHODOLOGY 
 
This is an audit to evaluate the outcome of various methods of management given to 
patients with unexplained infertility in the Infertility Clinic, Hospital USM. It is a retrospective 
and prospective cohort study, which was performed over three years duration from 1st 
December 2010 until 30th November 2013. 
4.1 REFERENCE POPULATION 
Patients with infertility in Hospital USM 
4.2 SOURCE POPULATION 
All patients who were diagnosed to have unexplained infertility, attending the Infertility Clinic 
in Hospital USM, between 1st December 2010 until 30th November 2013.  
4.3 RESEARCH ETHICAL ADHERENCE 
The audit was conducted after being presented to and approved by the Human Research 
Ethics Committee of USM (HREC). The letter of approval from the HREC is as in Appendix 
1. The permission to review the case notes of the patients was obtained from the Director 
Hospital of Hospital USM and the patients via phone calls. 
4.4 PATIENTS SELECTION AND PRE-ASSESSMENT  
There were two ways of patients’ recruitment into the study; the first cohort of patients was 
those who had attended the Infertility Clinic between 1st December 2010 until 31st December 
2012 and the second cohort of patients were recruited from those attending the Infertility 
Clinic from 1st January 2013 until 31st December 2013.  
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4.4.1 Patient selection for the 1st cohort of patients (1st December 2010- 
31st December 2012) 
For this cohort of patient, the list of the infertility patients was obtained from the Infertility list 
of attendance. The case notes of the patients were reviewed to select only those who were 
diagnosed to have unexplained infertility.  
Phone calls were made to these patients to obtain their consent for their case notes 
reviewed to obtain the clinical information. 
The management which was given was reviewed, together with the outcome of the 
management. 
4.4.2 Patient selection for the 2nd cohort of patient (1st January- 31st 
December 2013) 
A prospective study was performed on the second cohort of patients. The diagnosis of 
unexplained infertility was made when all the results for the baseline investigations for 
infertility (as stated in 4.4.3 ) was made. Informed consent to participate in the study was 
obtained from the patients. 
The patients were subsequently counseled for treatment, either to receive expectant 
management, controlled ovarian hyperstimulation (COH) without intrauterine insemination 
(IUI); COH alone, or COH with IUI; COH + IUI. The choice of treatment given was based on 
the overall patient’s demographic data, which looked into the age of the patient and the 
duration of infertility. The selection of treatment was made by the consultant in charge of the 
patient and patient’s decision after full counseling. 
4.4.2.1 Expectant management group 
Patients who were given the expectant management were given a 3-monthly follow-up to 
review if they were pregnant, until a maximum of 12 months. The time when they managed 
to get pregnant was documented. 
